Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

Inclusion Criteria: * 40-85 year old males * Patient is newly diagnosed with clinical Stage T1a-T2c prostate cancer based on transrectal guided extended prostate biopsy of at least 10 cores. * Patient elects to undergo 3D mapping biopsy at our center as part of prostate cancer management. * Patient will read, understand and sign the informed consent agreement * Patients must have a life expectancy of at least one year. * Gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4 * Percentage positive core rate \< 50% based on sextant or extended biopsy technique. * Prostate Volume (PV) \>15 grams. * Negative imaging studies ( if available) during the staging period such as Bone scan, MRI and CT scan if PSA\> 10 ng.dl before initiation of the study drug Exclusion Criteria: * Any 5α-reductase inhibitors medications within the past 12 months before enrollment. * Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors. * Anticipated blood donation within the next 90 days. * Serum PSA levels of \>20ng/dl. * Clinical evidence of metastatic prostate cancer. * Two documented urinary tract infections in the past year * CHF, MI (within 6 months) or other symptomatic CVS disease * Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric) * Enrollment in other studies for any disease in the past 30 days * Significant urinary incontinence * Diagnosis of cancer that in not considered cured, except BCC of skin * Prior transurethral resection of the prostate with a large tissue defect. * History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology * Previous or concurrent radiotherapy, hormonal therapy or chemotherapy